Compare OPXS & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OPXS | PLRX |
|---|---|---|
| Founded | 1987 | 2015 |
| Country | United States | United States |
| Employees | 72 | N/A |
| Industry | Electronic Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 94.1M | 81.1M |
| IPO Year | 2009 | 2020 |
| Metric | OPXS | PLRX |
|---|---|---|
| Price | $10.69 | $1.24 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 4 |
| Target Price | ★ $16.10 | $2.67 |
| AVG Volume (30 Days) | 31.7K | ★ 580.8K |
| Earning Date | 05-12-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 34.55 | 29.97 |
| EPS | ★ 0.03 | N/A |
| Revenue | ★ $24,530,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $350.00 | ★ N/A |
| Revenue Growth | ★ 17.63 | N/A |
| 52 Week Low | $6.10 | $1.09 |
| 52 Week High | $17.76 | $1.95 |
| Indicator | OPXS | PLRX |
|---|---|---|
| Relative Strength Index (RSI) | 31.62 | 42.22 |
| Support Level | $9.96 | $1.12 |
| Resistance Level | $13.89 | $1.37 |
| Average True Range (ATR) | 0.67 | 0.07 |
| MACD | -0.14 | -0.01 |
| Stochastic Oscillator | 12.01 | 34.09 |
Optex Systems Holdings Inc manufactures optical sighting systems and assemblies for the U.S. Department of Defense, foreign military applications, and commercial markets. Its products are installed on a variety of United States military land vehicles, such as the Abrams and Bradley fighting vehicles, light armored and security vehicles, and have been selected for installation on the Stryker family of vehicles. The company's operating segment includes Optex Systems Richardson, Applied Optics Center Dallas, and others. It generates maximum revenue from the Optex Systems Richardson segment. Some of its products include M17 Day/Thermal Periscope; DDAN / M36 Sights; Laser Protected Periscopes; Muzzle Reference Sensor, and others.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of integrin-based therapies. The company operates as a single reportable segment focused on developing and commercializing novel integrin-based treatments. Its lead product candidate, PLN-101095, is an oral small molecule targeting integrins for the treatment of solid tumors. The company also advances a pipeline of integrin-based programs across multiple disease areas through its proprietary drug discovery platform.